Phase III PEMPHIX study shows Roche ’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

Roche today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news